Q2 2025 EPS Estimates for Applied Therapeutics, Inc. (NASDAQ:APLT) Increased by Analyst

Applied Therapeutics, Inc. (NASDAQ:APLT) – Investment analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for shares of Applied Therapeutics in a research report issued to clients and investors on Wednesday, September 18th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.14) per share for the quarter, up from their prior forecast of ($0.15). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.25) EPS.

Several other research analysts have also commented on the stock. Citigroup increased their price target on shares of Applied Therapeutics from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday. Leerink Partners lifted their price target on shares of Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a research report on Thursday. Royal Bank of Canada reissued an “outperform” rating and set a $12.00 target price on shares of Applied Therapeutics in a research report on Wednesday, July 17th. Finally, William Blair raised Applied Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.50.

Applied Therapeutics Trading Down 3.8 %

APLT opened at $7.70 on Monday. Applied Therapeutics has a 1 year low of $1.79 and a 1 year high of $9.39. The stock has a fifty day moving average price of $5.81 and a 200 day moving average price of $5.32. The stock has a market cap of $879.86 million, a price-to-earnings ratio of -4.18 and a beta of 2.03.

Applied Therapeutics (NASDAQ:APLT) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $10.00 million.

Insiders Place Their Bets

In other news, CEO Shoshana Shendelman sold 119,591 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $5.93, for a total transaction of $709,174.63. Following the completion of the transaction, the chief executive officer now owns 4,690,839 shares of the company’s stock, valued at $27,816,675.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Applied Therapeutics

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. bought a new position in shares of Applied Therapeutics during the 2nd quarter worth about $54,000. Principal Financial Group Inc. acquired a new position in Applied Therapeutics in the second quarter worth about $54,000. SG Americas Securities LLC bought a new position in Applied Therapeutics during the second quarter worth about $87,000. Algert Global LLC acquired a new stake in Applied Therapeutics during the second quarter valued at approximately $110,000. Finally, Jump Financial LLC acquired a new stake in Applied Therapeutics during the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.